Introduction
============

The root of ginseng has been in widespread use for Chinese traditional medicine for millions of years. It has been suggested to have a varieties of pharmacological activities such as vasorelaxation, anti-inflammatory, antidiabetic, anticancer, antioxidation ([@B13]; [@B22]; [@B7]; [@B30]). The effects of ginseng are mostly attributed to a class of dammarane-type triterpene saponins known as ginsenosides. These ginsenosides are further classified according to their aglycone moieties as 20(S)-protopanaxadiol type (ginsenoside Rb~1~, Rb~2~, Rb~3~, Rc, and Rd) and 20(S)-protopanaxatriol (ginsenoside Re, Rg~1~, Rg~2~, and Rh~1~) ([@B20]). Ginsenoside Rb~1~ is one of prominent active constituents in the root of ginseng and accumulating evidence indicates that Rb~1~ possesses neuroprotection for central nervous system (CNS). Particularly, Rb~1~ was considered as a potent agent, which could protect brain from ischemia-reperfusion injury possibly by scavenging free radicals, preserving the structural integrity of the neurons, modulating the expression of apoptosis-associated proteins, inhibiting the expression of Beclin 1 and LC3 via activation of PI3K/Akt pathway, and upregulating levels of brain-derived neurotrophic factors ([@B11]; [@B19]; [@B38]; [@B20]; [@B7]; [@B23]).

Our previous study has determined pharmacokinetic and absolute bioavailability of Total Panax Notoginsenoside (TPNS) after intravenous administration of TPNS injection at the dosage of 10.0 mg/kg to rats. Results show that the largest content of Rb~1~ and its duration in brain tissue are up to about 1.4 μg/g and 24 h, whereas those of Rg~1~ are only about 0.2 μg/g and 1 h. Rb~1~ and Rg~1~ are present in the greatest amounts in TPNS, because the concentrations of Rb~1~ and Rg~1~ are in large amounts in rat plasma or excretory samples. The contents of Rb~1~ and Rg~1~ in TPNS are almostly equivalent, about 34 and 26%, respectively ([@B18]). This phenomenon indicates that Rb~1~ is capable of crossing the blood--brain barrier (BBB) into brain and the specific distribution of Rb~1~ in rat brain has no obvious correlation with its high content in TPNS. As we all know, the BBB is consisted of brain microvascular endothelial cells (BMEC) working together with astrocytes and pericytes, in which the physical barrier developed by the endothelial tight junctions and the transporter barrier resulting from membrane transporters strictly control the entry of endogenous and exogenous substances from the circulating blood into the CNS, therefore playing an essential role in brain homeostasis and protecting the CNS against many toxic compounds ([@B1]). The characteristics of the BBB include high electric impedance, low water conductivity, high reflection coefficient, and low diffusion permeability of water-soluble substances. Evidence from the above described indicates that the impenetrability of BBB constitutes a barrier to most polar molecules and macromolecules delivery to brain parenchyma ([@B4]). The polarity of Rb~1~ is high and its molecular weight is also large, about 1109.29. So we speculate that some transporters in BMEC membranes are possibly involved in the transport of Rb~1~ across the BBB. However, what transporter involved in the transport of Rb~1~ across the BBB has not been reported in the present study so far.

GLUT proteins are encoded by the SLC2 genes and belong to members of the major facilitator superfamily of membrane transporters, which primary function is to transport extracellular glucose from interstitial fluid across the cellular plasma membrane by a passive and facilitative transport process along with the downward gradient concentration of glucose ([@B33]). GLUT proteins consist of 14 members, and GLUT1 and GLUT3 are mostly expressed in the CNS ([@B27]). The ginsenoside Rb~1~ possesses two glucose moieties at the C-3 and C-20 positions, respectively, so we hypothesize that GLUT1 or GLUT3 in BMEC membranes is involved in the transport of Rb~1~ across cell membranes.

Therefore, the aim of this study was to demonstrate the transport mechanism of Rb~1~ across the BBB into brain. First, we measured the uptake kinetics of Rb~1~ using rBMEC *in vitro* for the sake of obtaining evidence for active uptake of Rb~1~ into cells. We then further investigated the effects of multiple inhibitors of transporters on the uptake of Rb~1~ into rBMEC. Finally, the brain-to-plasma concentration ratio value of Rb~1~ (*K*~p~) in the phloretin-treated normal rats was measured using LC--MS/MS method for further obtaining evidence that transport of Rb~1~ across the BBB is actively facilitated by GLUT1 or GLUT3 transporter.

Materials and Methods {#s1}
=====================

Materials
---------

Ginsenoside Rb~1~ and digoxin (internal standard, IS) were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Collagenase type II, bovine serum albumin (BSA), gelatin, phloretin, and [D]{.smallcaps} (+)-glucose were purchased from Sigma (Sigma-Aldrich Co. LLC., United States). Fetal bovine serum (FBS) was purchase from GIBCO (Invitrogen Corporation, United States). Dulbecco's modified Eagle's medium (DMEM-F12) was purchased from HyClone (Thermo Scientific, United States). Rabbit anti-GLUT1, rabbit anti-GLUT3, and goat anti-rabbit IgG (H+L) conjugated with the appropriate horseradish peroxidase were purchased from Abcam. All other chemicals and reagents were of analytical or LC--MS grade as appropriate.

Animals
-------

Male Sprague-Dawley rats (220--250 g) were supplied by Center of Experimental Animals, Shanghai First People's Hospital Affiliated Shanghai Jiao Tong University. Animals were housed under a constant environment condition (temperature, 25 ± 1°C; humidity, 50 ± 5%) with free access to standard laboratory diet and water. Sprague-Dawley neonate rats of 10 days old were used. All the experiments were performed in accordance with China's Guidelines for Care and Use of Laboratory Animals.

Isolation and Primary Culture of rBMEC
--------------------------------------

Isolation and culture of rat brain microvessel endothelial cells were operated according to previous studies with some modifications ([@B21]). The isolated rBMEC was seeded in cultured flasks coated with 2% gelatin and cultured in culture medium. The culture medium consisted of DMEM/F12 supplemented with 20% FBS, 2 mM [L]{.smallcaps}-glutamine, heparin (50 mg/L), 100 IU/mL penicillin, 100 μg/mL streptomycin, and NaHCO~3~ (0.5 g/L). On the first day after seeding, the culture medium was replaced, after which the culture medium was replaced every 2 days. At 5--6 days, the rBMEC was transferred to 6-well plates coated with gelatin and cultured in an incubator with a saturated humidity at 37°C in 5% CO~2~ and 95% air. Transport studies were performed when cells reached 100% confluency. The endothelial phenotype of the rBMEC was identified by staining for the endothelial cell marker vWF using a confocal laser scanning microscope (Leica TCS SP8).

Transport Studies
-----------------

When rBMEC was grown to 100% confluency in gelatin-coated 6-well plates, uptake experiments were performed. Briefly, the cultured cell monolayer was washed three times with 1 mL of pH 7.4 Hanks' balanced salt solution (HBSS). The cultured rBMEC was pre-incubated for 30 min in 1 mL HBSS at 37 or 4°C. After pre-incubation, the HBSS solution was removed by suction, and HBSS (1 mL) containing 60 μg/mL Rb~1~ was added to initiate uptake. Then the cells were incubated at 37 or 4°C at a set time (5, 10, 15, 30, 60, 120, and 240 min). After the end of the incubation, the incubation solution was aspirated and the monolayers were carefully washed three times with 1 mL ice-cold HBSS to terminate the uptake. Then, 0.5 mL ultrapure water was added to each incubated well, and the material in the wells was frozen (at -80°C)/thawed (at room temperature) repeatedly four times to lyse cells. After the solubilized, the monolayer supernatants were collected and 10 μL was injected into LC--MS/MS to determine Rb~1~ concentration. The protein contents of the cell monolayers were measured by the method of Bradford using BSA as the standard ([@B2]). Uptake was expressed as the cell-to-medium ratio (μL/mg protein or μL/mg protein/min) and termed the volume of distribution (*V*~d~), obtained by dividing the uptake amount by the concentration of substrate in the transport medium. *V*~d~ is derived from the ratio of ng/mg protein to ng/μL buffer.

In order to assess the kinetic parameters, Rb~1~ uptake data (7.5 to 960 μg/mL for 120 min) were analyzed using Michaelis-Menten plots based on the following equation: $\mathit{V} = \frac{\mathit{V}_{\max} \times \mathit{S}}{\mathit{K}_{m} \times \mathit{S}} + \mathit{P}_{diff} \times \mathit{S}$, where *V* is the initial uptake rate of substrate (nmol/mg protein/min), *V*~max~ is the maximum uptake rate (nmol/mg protein/min), *S* is the concentration of Rb~1~ in the medium (μM), *K*~m~ is the Michaelis-Menten constant (μM), and *P*~diff~ is the non-saturable uptake clearance (μL/mg protein/min), respectively ([@B14]). The uptake data were fitted to the above equation by nonlinear least-squares regression analysis with Graphpad Prism 5.0 software.

Transporter Inhibition Assays
-----------------------------

Our study showed that the uptake of Rb~1~ by rBMEC was dependent on time, concentration, and temperature. A steady-state uptake occurred at 120 min. In the present study, the uptake at 120 min was selected to measure the effect of test agents on the transport characteristics of Rb~1~. Rb~1~ concentration was set to be 60 μg/mL. The rBMEC was seeded out in 6-well plates, allowed to adhere, and grown to confluency. To study the transport mechanisms, uptake of Rb~1~ was carried out in the presence of a metabolic energy inhibitor and a series of established transporter inhibitors. The impact of these inhibitors on Rb~1~ uptake by rBMEC was assessed at the steady state at 37°C. NaN~3~ (500 μM), probenecid (100 μM), CsA (25, 50, and 100 μM), or phloretin (5 μM) was added to inhibit different transport systems. In the inhibition study, to further assess the effect of phloretin on Rb~1~ uptake into rBMEC, the cells were incubated at 37°C at a set time (5, 15, 30, 60, and 120 min). Uptake was measured after incubation with Rb~1~ in the presence of phloretin at the concentration of 5 μM.

In the competition experiments, Rb~1~ uptake (30--960 μg/mL) was measured in the absence and presence of [D]{.smallcaps}-glucose (100 mM) which is a principal physiological substrate of GLUT1. Briefly, cells were grown in 6-well plates for 7 days before their medium was removed, pre-incubated with warm glucose-free Hanks' solution for 30 min. Subsequently, samples and controls were treated as described transport studies, but this time in addition with 100 mM [D]{.smallcaps}-glucose to the various concentrations of Rb~1~ in glucose-free Hanks' solution at 37°C for 120 min.

Cell Viability Assessment
-------------------------

The cytotoxic effects of the test agents used in this study were assessed on confluent monolayers of cells in 96-well plates using a CCK-8 assay. Cells were subjected to a 200 μL/well of each drug in Hanks' solution at the concentrations used in the experiments, followed by incubation for another 4 h. Then, 10 μL Cell Counting Kit-8 (CCK8, Dojindo) solution was added to each well. Plates were incubated for additional 4 h. Absorbance readings at 450 nm were obtained using a spectrophotometer (Thermo Varioskan) and expressed as percentage viability compared to control untreated cells.

Effect of Phloretin on Distribution of Rb~1~ in Plasma and Brain of Normal Rats
-------------------------------------------------------------------------------

Rats were randomly divided into two groups in 36 of each group. One group served as the control and another group were treated with phloretin. Dose of phloretin was set to be 5 mg/kg. Rb~1~ (10 mg/kg, *i.v.*) was administered to the experimental rats after *i.v.* administration of phloretin or saline for consecutive 1 week. Six rats from each group were selected and the blood samples were collected into heparinized Eppendorf tubes via the abdominal aorta at 0.5, 2, and 6 h after Rb~1~ administration. Then, brain samples were immediately collected. The plasma samples were obtained by centrifuging at 1000 × *g* for 10 min. Plasma and brain samples were frozen at -80°C until analysis.

HPLC--MS/MS Method for Rapid Quantification of Rb~1~ in Cells, Plasma, and Brain
--------------------------------------------------------------------------------

HPLC--MS/MS was composed by a Shimadzu LC-20A chromatographic system and an API 4000 mass spectrometer equipped with electrospray ionization (ESI) source system. MS/MS detection was performed on an API 4000 mass spectrometer using multiple reaction monitoring (MRM) mode by monitoring the fragmentation of *m*/*z* 1107.6 → 179.0 for Rb~1~ and *m*/*z* 779.4 → 345.2 for digoxin (IS). Chromatographic separations were carried out on a Shim-pack XD-ODS column (2.0 mm × 30 mm, 2.2 μm) with a Shim-pack GVD-ODS (2.0 mm × 5 mm, 4.6 μm) guard column (Shimadzu, Japan) at a flow rate of 0.28 mL/min using 10 mM acetic acid in water (phase A) and methanol (phase B) as mobile phase. A linear step gradient elution was performed as followed: phase B was increased from 45 to 90% within the first 3 min, and decreased to 45% within the next 3 min (total gradient time: 6 min). A 10 μL sample was injected into the system with the auto-sample conditioned at 4°C and column temperature maintained at 40°C.

The biological samples (100 μL) were placed in a 1.5 mL Eppendorf tube, and mixed with 10 μL IS solution (500 ng/mL) for 3 min by vortexing. The mixture was extracted with methanol (0.9 mL) by vortexing, and then centrifuged at 14,000 rpm for 5 min. The supernatant (0.8 mL) was transferred to a new 1.5 mL Eppendorf tube and evaporated to dryness under vacuum. The dried residue was reconstituted with 100 μL methanol, vortex-mixed for 30 s, and centrifuged at 14,000 rpm for 5 min. Finally, 10 μL of the supernatant liquid was immediately subjected to HPLC--MS/MS analysis. The system control and data analysis were performed by AB Sciex Analyst software (the software version: Analyst 1.5.1). Retention time for Rb~1~ was *t*~R~ = 3.80 ± 0.01 min and for IS digoxin *t*~R~ = 3.13 ± 0.01 min. The lowest limits of quantitation of Rb~1~ in cell lysate, plasma, and brain homogenate were 1, 2.5, and 1 ng/mL, respectively. The recoveries were higher than 90%; the relative standard deviations (SD) of intra-day and inter-day were lower than 10%.

Western Blotting
----------------

Total proteins were extracted and 60 μg of each protein was separated on SDS-10% polyacrylamide gels. Proteins on the gel were transferred to PVDF membrane (Merck-Millipore). Blots were blocked with 5% skimmed milk dissolved in PBS containing 0.1% Tween-20 (PBST) for 2 h at room temperature. The membrane was incubated with primary antibody at 4°C overnight. Washing of the blots with PBST three times was followed by incubation with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. After washing, the chemiluminescence signal was monitored using the ChemiDoc XRS+ system (Bio-Rad, Hercules, CA, United States). Densitometric semi-quantitative analysis of protein bands was carried out using Image J.

Statistical Analysis
--------------------

All data were expressed as mean ± SD. Statistical significance of difference among groups was evaluated by one-way of analysis of variance (ANOVA) and the Student's *t*-test. A *P*-value of \<0.05 indicated a statistical significance.

Results
=======

Uptake Kinetics of Rb~1~ by rBMEC
---------------------------------

Uptake of Rb~1~ by rBMEC was evaluated at various intervals (5, 10, 15, 30, 60, 120, and 240 min) to obtain the optimal time for uptake studies. **Figure [1](#F1){ref-type="fig"}** shows the time course of the uptake of Rb~1~ by rBMEC at a concentration of 60 μg/mL at 37 and at 4°C. Rb~1~ uptake increased linearly with time until 120 min, and a plateau of accumulation was observed at 120--240 min. Accordingly, uptake at 120 min was used for subsequent kinetic and inhibition studies. However, in contrast, the uptake rate at 4°C was slow and the intracellular amounts of Rb~1~ were about two to threefold greater at 37°C than those at 4°C. This indicated transporters in rBMEC membranes were involved in the Rb~1~ transport.

![Time course of Rb~1~ uptake by rBMEC. Uptake of Rb~1~ (60 μg/mL) was measured at 37°C (black markers) and 4°C (white markers) with primary rBMEC cultured on 6-well plates for different times. Each point represents the mean ± SE (*n* = 3). Asterisks show a significant difference (^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 versus white markers).](fphar-09-00398-g001){#F1}

To study the mechanism of Rb~1~ transport, uptake of Rb~1~ by rBMEC was examined at various concentrations (7.5--960 μg/mL) at steady state and the kinetics parameters (*K*~m~ and *V*~max~) were investigated by fitting the data to the *Michaelis-Menten equation*. As shown in **Figure [2A](#F2){ref-type="fig"}**, initial uptake of Rb~1~ showed concentration dependency. Kinetics analysis provided a *K*~m~ value of 119.2 ± 15.6 μM and a *V*~max~ of 0.0034 ± 0.0003 nmol/(mg protein ⋅ min). The Eadie--Hofsee plot for saturation uptake, fitted by subtraction of nonsaturable uptake from total uptake, approximately appeared a straight line (*R*^2^ = 0.9066), indicating involvement of a simple passive membrane diffusion (**Figure [2B](#F2){ref-type="fig"}**).

![Concentration-dependence of Rb~1~ uptake **(A)** into rBMEC and the Eadie--Hofstee plot **(B)**. rBMEC was incubated in Rb~1~ solution at different concentration (7.5, 15, 30, 60, 120, 240, 480, and 960 μg/mL) at 37°C for 120 min. Cells were lysed and the intracellular amount of Rb~1~ was evaluated by LC--MS/MS. Each point represents the mean ± SE (*n* = 3). The solid curve, solid line, and curve represent estimated total, nonsaturable, and saturable uptakes, respectively **(A)**. *V* and *S* represent initial uptake velocity \[nmol/(mg protein ⋅ min)\] of the saturable component and concentration of Rb~1~ **(B)**.](fphar-09-00398-g002){#F2}

Inhibition of Rb~1~ Uptake
--------------------------

To clarify whether the accumulation of Rb~1~ in rBMEC was not only related to a simple passive diffusion, but to facilitated diffusion, we performed the effects of various inhibitors of transporters that facilitate the uptake of Rb~1~ into rBMEC. As shown in **Figure [3](#F3){ref-type="fig"}**, while no statistically significant differences were observed with inhibitors of the ABCB1 (P-gp, CsA) ([@B36]), organic anion-transporting polypeptides (OATPs, probenecid) ([@B12]), and metabolic energy (NaN~3~) ([@B14]), a significant decrease (*^∗∗^P* \< 0.01 versus the control) of Rb~1~ uptake into rBMEC was seen in the presence of the inhibitor phloretin that inhibits glucose transporters (GLUT1) ([@B5]). This result indicated that Rb~1~ uptake crossing rBMEC membranes was independent of ATP and was actively transported by GLUT1-mediated facilitated diffusion.

![Effect of ATP-depletion and influx or efflux transporter inhibitors on Rb~1~ uptake into rBMEC. Rb~1~ uptake (60 μg/mL) was measured in the absence (control) or presence of sodium azide (NaN~3~, 500 μM), probenecid (100 μM), cytochalasin A (CsA, 25, 50, and 100 μM), and phloretin (5 μM) at 37°C for 120 min. Each column represents the mean ± SE (*n* = 3) with significant differences from control shown as ^∗∗^*P* \< 0.01.](fphar-09-00398-g003){#F3}

In order to investigate whether the changes in Rb~1~ uptake by rBMEC in presence of the tested agents resulted from cell damage caused by the agents used, cells were incubated in Hanks' solution containing of 500 μM NaN~3~, 100 μM probenecid, 25, 50, and 100 μM CsA, or 5 μM phloretin at 37°C for 4 h. Proliferation of rBMEC exposure to the test agents used was measured by CCK-8 assay. Compared with the control, no statistically significant differences existed (*P* \> 0.05 versus the control, **Figure [4](#F4){ref-type="fig"}**). Thus, we concluded that the agents used did not have cytotoxicity at the concentration used, and that changes in the uptake of Rb~1~ did not result from cell damage. Phloretin, which significantly inhibited the uptake of Rb~1~ by rBMEC, was selected for further study.

![Cytotoxicity of test agents used in the study. The viability of rBMEC with a confluent monolayer exposure to the test agents used was examined by CCK-8 assay. Each column represents the mean ± SE of five replicates. Compared with the control, there was no statistically significant differences (*P* \> 0.05).](fphar-09-00398-g004){#F4}

Inhibition of Phloretin on Rb~1~ Uptake Into rBMEC
--------------------------------------------------

In order to further investigate the effect of phloretin on Rb~1~ uptake into rBMEC, the time course of Rb~1~ uptake in the absence or presence of 5 μM phloretin was evaluated at 37°C. As shown in **Figure [5A](#F5){ref-type="fig"}**, the cell-to-medium (C/M) ratio of Rb~1~ was increased with time, but it was found that phloretin significantly decreased the C/M ratio of Rb~1~, especially from min 30 to 120. GLUT1 and GLUT3, encoded by the SLC2A1 and SLC2A3 gene, respectively, are 2 of 14 facilitative GLUT transporter members and are mainly expressed in CNS. To see whether the decreased C/M ratio of Rb~1~ was correlated with the expression level of GLUT1 or GLUT3 in rBMEC, western blot assay was performed (**Figure [5B](#F5){ref-type="fig"}**). Statistical analysis showed that the expression levels of GLUT1 at 30, 60, and 120 min were significantly lower than that of control (**Figure [5C](#F5){ref-type="fig"}**, ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 versus the control). However, compared with the control, there was no significant difference in the expression level of GLUT3. These data indicated that the decreased C/M ratio of Rb~1~ was correlative well to the down-regulated function and level of GLUT1 in rBMEC.

![Effect of phloretin on Rb~1~ uptake into rBMEC. **(A)** To assess the roles played by GLUT1 in the transport of Rb~1~, the cellular uptake amount of Rb~1~ in confluent monolayers of rBMEC in 6-well plates was measured with 60 μg/mL Rb~1~ alone, or together with 5 μM phloretin at the designated time intervals at 37°C. Each point represents the mean ± SE (*n* = 3). Asterisks show a significant difference, ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 versus GLUT1 inhibitor groups. **(B)** Western blot assay was performed to evaluate the expression level of GLIUT1 and GLUT3 in rBMEC treated together with phloretin and Rb~1~ at the designated time intervals. **(C)** Relative protein level was quantitated using Image J. Each point represents as the mean ± SE (*n* = 3), with significant differences from control shown as ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01, GLUT1 inhibitor groups versus control, using GAPDH as an internal control for protein loading.](fphar-09-00398-g005){#F5}

Competitive Inhibition of [D]{.smallcaps}-Glucose on Rb~1~ Uptake by rBMEC
--------------------------------------------------------------------------

While GLUT1 is able to transport galactose, mannose, and glucosamine, its principal physiological substrate is glucose. Under normal physiological conditions, the brain is absolutely dependent on glucose as a fuel source. GLUT1, as the major GLUT isoform expressed in brain endothelial cells, plays an important role in glucose transport across the BBB ([@B37]). In the initial experiments, we analyzed the uptake characteristics of Rb~1~ by rBMEC. When we added the inhibitor phloretin of GLUT1, we observed significantly reduced C/M ratio of Rb~1~ uptake into rBMEC. Likewise, in Lineweaver--Burk plot of the inhibitory effects on the uptake of Rb~1~, the plots of Rb~1~ uptake in the absence and presence of [D]{.smallcaps}-glucose intersected at the ordinate axis (**Figure [6](#F6){ref-type="fig"}**), indicating that [D]{.smallcaps}-glucose competitively inhibited Rb~1~ uptake with a *K*~i~ value of 885 μM.

![Lineweaver--Burk plot of the inhibitory effect of [D]{.smallcaps}-glucose on Rb~1~ uptake into rBMEC. Uptake profile of Rb~1~ (30--960 μg/mL) was measured in the absence (white marker) or presence of 100 mM [D]{.smallcaps}-glucose (black marker) at 37°C for 120 min. Each point represents the mean ± SE (*n* = 3).](fphar-09-00398-g006){#F6}

Effects of Phloretin on Distribution of Rb~1~ in Plasma and Brain of Normal Rats
--------------------------------------------------------------------------------

Except for the time point of 0.5 h after a single *i.v.* administration of Rb~1~ to the normal rats given phloretin for consecutive 1 week, plasma concentrations of Rb~1~ in the phloretin-treated normal rats at 2 h and 6 h were no statistically significant differences than those in the untreated normal rats. Whereas cerebral concentrations of Rb~1~ in the phloretin-treated normal rats were significantly lower than those in the untreated normal rats (**Table [1](#T1){ref-type="table"}**). As a result, the brain-to-plasma concentration ratio of Rb~1~ in the phloretin-treated normal rats appeared to be significantly lower than that in the untreated normal rats, indicating that phloretin inhibits the transport of Rb~1~ across the BBB. To see whether the decreased brain--plasma concentration ratio of Rb~1~ was also related to the expression level change of GLUT1 or GLUT3 in the phloretin-treated normal rats, western blot assay was performed. The western blot results further showed that the expression levels of GLUT1 in the brain of normal rats given phloretin for 1 week were significantly decreased than those in the untreated normal rats (*P* \< 0.05, **Figure [7](#F7){ref-type="fig"}**). Although phloretin also binds to the GLUT3, it potently inhibits the GLUT1-type glucose transporter ([@B24]). These results demonstrated that the decreased brain--plasma concentration ratio of Rb~1~ was correlated well with the decreased function and level of GLUT1 in the phloretin-treated normal rats, conforming the involvement of GLUT1 in Rb~1~ transport across the BBB into brain.

###### 

Effect of phloretin on Rb~1~ distribution in plasma and brain of normal rats.

                                                             0.5 h          2 h              6 h                                            
  ---------------------------------------------------------- -------------- ---------------- -------------- ---------------- -------------- ----------------
  Plasma concentration (μg/mL)                               69.33 ± 4.5    48.7 ± 2.9\*\*   39.7 ± 4.1     33.2 ± 1.4       35.2 ± 3.0     27.0 ± 1.5
  Brain concentration (ng/g brain)                           489.6 ± 58.3   105.1 ± 15.1\*   193.8 ± 11.1   84.8 ± 4.1\*\*   114.2 ± 24.0   39.9 ± 4.9\*
  Brain-to-plasma concentration ratio (*K*~p~, μL/g brain)   7.09 ± 1.01    2.15 ± 0.19\*    4.9 ± 0.35     2.56 ± 0.06\*    3.24 ± 0.53    1.59 ± 0.005\*
                                                                                                                                            

The rats were treated with phloretin (5 mg/kg/day,

i.v.

) for 1 week consecutively. The control rats only received saline. The Rb

1

concentrations in plasma and brain were measured at 0.5, 2, and 6 h after injection of phloretin on day 7. Each value represents the mean ± SE (

n

= 6). Asterisks show a significant difference,

∗

P

\< 0.05 and

∗∗

P \<

0.01 versus phloretin-untreated control groups.

![Expression of GLUT1 and GLUT3 in normal rat brain. **(A)** Western blot assay was to estimate whether the decreased brain--plasma concentration ratio of Rb~1~ was correlated with the expression level of GLUT1 or GLUT3 in normal rat brain. **(B)** Relative protein level was quantitated using Image J. GAPDH was stained as an internal control for protein loading. Each column represents the mean ± SE (*n* = 3), with significant differences from the phloretin-untreated control groups shown as ^∗^*P* \< 0.05.](fphar-09-00398-g007){#F7}

Discussion
==========

In the present study, Rb~1~ transport across the BBB was characterized by means of both *in vitro* uptake studies using primary rBMEC and *in vivo* brain--plasma concentration ratio (*K*~p~). Uptake of Rb~1~ by rBMEC was time- and temperature-dependent. The uptake of Rb~1~ increased linearly with time until 120 min, and a plateau of accumulation was observed at 120--240 min. However, the intracellular amounts of Rb~1~ at 4°C were lower than those at 37°C (**Figure [1](#F1){ref-type="fig"}**). Uptake of Rb~1~ was concentration-dependent, with *K*~m~ and *V*~max~ values of 119.2 μM and 0.0034 nmol/(mg protein ⋅ min), respectively. The saturable component (*V*~max~/*K*~m~) and the nonsaturable component (*P*~diff~) of Rb~1~ transport were calculated to be 0.03 and 0.0023 μL/(mg protein ⋅ min), respectively. Thus, 90% of the total Rb~1~ uptake is accounted for by the saturable component in the low concentration range. These results indicated that uptake of Rb~1~ into rBMEC was not solely driven by a simple passive diffusion process. In our *in vivo* study, the brain-to-plasma concentration ratios of ginsenoside Rb~1~ measured at 0.5, 2, and 6 h in untreated normal rats were significantly larger than that in phloretin-treated normal rats, suggesting carrier-mediated active uptake transport into brain across the BBB.

To further study the effects of transport systems with Rb~1~, other transporter inhibitors were used to evaluate transport activity of metabolic energy, Pgp, OATPs, and GLUT1. Pgp is one of the numbers of the ABC transporter superfamily, mediating the efflux from brain to blood and playing an import role *in vivo* to protect the brain from toxic compounds. OATPs play large roles in transporting endogenous molecules across cell membranes. GLUT1 is expressed in many cell types, but is at its highest level in the human erythrocyte membrane, through which glucose can freely keep in equilibrium between the serum and the red cell cytoplasm. And furthermore, GLUT1 is a major GLUT isoform expressed in cerebral endothelial cells, which plays an important role in cerebral glucose uptake. Cytochalasin B and phloretin would inhibit the GLUT1 activity ([@B16]; [@B34]). Rb~1~ uptake by rBMEC was significantly decreased by phloretin, but was not inhibited by the inhibitors of metabolic energy (NaN~3~), P-gp (CsA), and OATPs (probenecid) (**Figure [3](#F3){ref-type="fig"}**). Although the GLUT1 can be capable of transporting galactose, mannose, and glucosamine, its principle physiological substrate is [D]{.smallcaps}-glucose. The *K*~i~ value for GLUT proteins is the concentration of blood glucose at which delivery into the cell, and GLUT1 is a high-affinity glucose transporter with a *K*~i~ for glucose of around 1 mM ([@B3]). In our study, the uptake of Rb~1~ was competitively inhibited by [D]{.smallcaps}-glucose with a *K*~i~ value of 885 μM. Therefore, the results indicate that the transport of Rb~1~ across BBB is mainly mediated by GLUT1, although we cannot deny the possibility that Rb~1~ is transported by any other transporter(s).

In the inhibition experiments when we determined the effect of phloretin on Rb~1~ uptake into rBMEC, we found a statistical decrease of the C/M ratio of Rb~1~ by phloretin after 30 min. Western blot assay showed that the decreased C/M ratio of Rb~1~ uptake into rBMEC was correlated well to the reduced level of GLUT1 in phloretin-treated rBMEC (**Figure [5](#F5){ref-type="fig"}**). These results are suggestive of a transporter-mediated uptake of Rb~1~ into rBMEC, possibly via GLUT1. This concept was further supported by evidence that the decreased brain-to-plasma concentration ratio of Rb~1~ was also correlative well with the down-regulated function and level of GLUT1 in phloretin-treated normal rats. The brain-to-plasma concentration ratio of a drug represents the degree of a drug's penetration into brain across BBB. In the study, it was found that the brain--plasma concentration ratios of Rb~1~ in the phloretin-treated normal rats were significantly lower than those in the phloretin-untreated normal rats. And the expression level of GLUT1 in the phloretin-treated normal rats was down-regulated in comparison with the untreated control rats. However, we found the decreased level of GLUT3 in the phloretin-treated normal rats. Phloretin is the potent inhibitor of GLUT1-type glucose transporter although it is not highly selective and also binds to other GLUT isoforms ([@B24]). Thus, we may conclude that GLUT1 is involved in the Rb~1~ transport across the BBB into brain from circulating blood.

Due to a facilitated uptake of Rb~1~ into rBMEC, it can be inferred that Rb~1~ transport will be also observed in other cells that express GLUT1. GLUT1 is a 492-amino acid residues protein. It is expressed in most tissues at its highest level in fetal tissues ([@B39]). The highest levels in adult humans are found in cerebral microvessels, colon, and kidney, but very low in skeletal muscle and liver ([@B8]). Some researchers have found that GLUT1 has a significant effect on the survival of the pre-implantation embryo ([@B25]). GLUT1 is also found in astrocytes, which has been considered to supply glycolytically derived lactate to neurons for a major energy source ([@B29]). The erythrocyte-type transporter protein GLUT1 has been also extensively investigated. And, this is possible that the transport in or on erythrocytes promotes an efficient compound exchange between the red cell and the capillary endothelium ([@B9]). The meaning of uptake of drugs by erythrocytes has been specifically reported in the early stages ([@B9]; [@B10]). The distribution of some molecules into erythrocytes can promote their storage, transport, and metabolism, and then may affect their activity ([@B17]). Because of erythrocytes consisting of a transport system with high capacity and low affinity compared to plasma proteins, the elimination of half-life of substances from different blood constituents might differ and the discharge from erythrocytes is often faster than the loss from plasma proteins ([@B32]). Therefore, our future study will focus on the uptake of Rb~1~ by red blood cells, further confirming the involvement of GLUT1 in Rb~1~ transport across cell membranes.

Our study has a number of limitations. The inhibition experiments were done with Rb~1~ in the presence of various transporter inhibitors. Phloretin, an inhibitor of GLUT1, also interacts with other transporters such as the monocarboxylate transporter ([@B28]), sodium glucose co-transporter SGLT-1 ([@B31]), volume-sensitive chloride channels ([@B6]), aquaporin water channels ([@B26]), or urea transporter ([@B15]). However, it reminds us that the significant decreased uptake of Rb~1~ by rBMEC in the presence of phloretin and [D]{.smallcaps}-glucose supports our point of view that uptake of Rb~1~ by rBMEC is an active transport process. Yet it cannot be excluded that additional transport processes play a major role as it was proposed by [@B35] that carrier-mediated and passive transport processes can coexist. Finally, we did not study whether the glucose influx in rBMEC was influenced by Rb~1~ or the precise type of interaction with the GLUT1 transporter. The type of interaction with the GLUT1 seems to be complicated as compounds can behave as competitive or noncompetitive inhibitors regarding glucose uptake or exit while the transporter has binding sites for phloretin ([@B17]). Although we have no further details on Rb~1~ transport, we discovered that it was the GLUT1 that involved in Rb~1~ transport across BBB.

To summarize, our present results indicate that the uptake of Rb~1~ into rBMEC is diminished in the presence of phloretin and [D]{.smallcaps}-glucose, suggesting that it is actively taken up into rBMEC, possibly via GLUT1. *In vivo* study using phloretin treatment suggests that GLUT1 plays a major role in active transport of Rb~1~ across BBB into brain from circulating blood.
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